Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07265479 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Organon and.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07265479 is a Phase 3 study of Atopic Dermatitis that is actively recruiting participants, run by Organon and. The registered enrollment target is 180 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07265479, a Phase 3 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Organon and.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Conditions Studied
Interventions
- DRUG Vehicle Cream
- DRUG Tapinarof cream, 1%
Study Locations (20)
California
- Dermatology Research Associates - Los Angeles
- Integrative Skin Science and Research - Sacramento
- Allergy and Asthma Medical Group and Research Center - San Diego
- Clinical Trials Research Institute - Thousand Oaks
Florida
- Skin Care Research, LLC. - Boca Raton
- APEX Clinical Trials - Jacksonville
- TruDerm Research - Wellington
Illinois
- Northwestern University - Chicago
- Endeavor Health Clinical Operations - Skokie
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
- The Indiana Clinical Trials Center, PC - Plainfield
Alabama
- AllerVie Clinical Research - Birmingham
Arkansas
- Dermatology Trial Associates - Bryant
Colorado
- Clarity Dermatology - Castle Rock
Georgia
- Cleaver Medical Group Dermatology, Inc - Cumming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07265479
The ClinicalTrials.gov registry entry for NCT07265479 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (70% lower). The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT07265479 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT07265479 about?
NCT07265479 is a clinical study titled "A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis". The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
What is the current status of trial NCT07265479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2025-12-29. Estimated completion is 2028-01.
What conditions does trial NCT07265479 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT07265479?
The interventions under investigation include: Vehicle Cream (DRUG), Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT07265479?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07265479 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.